Teijin Limited and BioVaram, the brand name of the UR Advanced Therapeutics Pvt Ltd. (URAT), announced that they have signed a business alliance agreement to explore opportunities for expanding usage of Teijin Group’s implantable medical devices and regenerative medicine products in India, as well as introducing BioVaram’s product portfolio into the Japanese market.

The two companies share a vision to address unmet medical needs in Japan—one of the world’s most advanced healthcare markets—and India, where healthcare innovation is accelerating. This alliance aims to leverage each company’s strengths to deliver cutting-edge solutions across both nations.

Under the agreement, Teijin and BioVaram will explore:

- Regulatory approval and commercialization of SYNFOLIUM^Ⓡ, a cardiovascular repair patch by Teijin Medical Technologies Co., Ltd., in India.

- Opportunities for expanding use of Japan Tissue Engineering Co., Ltd.’s regenerative medicine products in India. Japan Tissue Engineering (J-TEC) is part of the Teijin Group.

- Development and commercialization in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.

Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited., said “The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin’s global expansion in the fields of regenerative medicine and implantable medical devices. By combining the exceptional technological capabilities and extensive expertise of both companies across the distinct markets of Japan and India, we are confident in our ability to deliver innovative therapies that address unmet medical needs in both countries.”

Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, remarked, “This MoU with Teijin Limited marks the beginning of a journey to bring India’s next-generation biotech innovations onto the global stage. It reinforces BioVaram’s vision to build transformative biotech innovations in India together with global partners. This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram’s products to global markets. Together, we are shaping a future where biotechnology is transformative, sustainable, and deeply humane” .”

Teijin established its Regenerative Medicine and Implantable Medical Devices division in 2022 by, integrating Teijin Medical Technologies, which manufactures bioabsorbable implantable devices; J-TEC, a pioneer in regenerative medicine; and Teijin Regenet Co., Ltd., a dedicated contract development and manufacturing organization (CDMO) for regenerative therapies. The group continues to grow with a mission to provide treatments that restore lost tissue and functions for patients.

Headquartered in Hyderabad, India, BioVaram is a rapidly growing biotechnology company recognized for its innovative regenerative medicine solutions. BioVaram offers AI-designed peptides, exosomes for therapeutic and diagnostic use, and bio-derived materials. The company has earned multiple awards, including being named a “Top 5 Startup” at BioAsia 2024.

Moving forward, the two companies will assess business feasibility, regulatory pathways, technical integration, and market needs to advance these initiatives. They will also collaborate on product development and manufacturing in cell and gene therapy, and pursue plans for introducing SYNFOLIUM^Ⓡ in India. By sharing market insights and regulatory information, Teijin and BioVaram aim to build a robust partnership that accelerates innovation in both countries.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.

Teijin Group remains committed to achieving its fiscal 2030 sales target of JPY 20 billion in regenerative medicine by actively capturing global demand, strengthening its business foundation through facility expansion and talent development, and pursuing strategic partnerships worldwide.